预约演示
更新于：2025-07-19
Levobupivacaine Hydrochloride
盐酸左布比卡因
更新于：2025-07-19
概要
基本信息
原研机构 |
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H29ClN2O |
InChIKeySIEYLFHKZGLBNX-NTISSMGPSA-N |
CAS号27262-48-2 |
关联
536
项与 盐酸左布比卡因 相关的临床试验NCT06926764
Intertransverse Process Block to Improve Quality of Recovery After Cardiac Surgery With Sternotomy: a Prospective Randomised Controlled Trial
CTRI/2024/12/077557
A Prospective Randomised Comparative Study of 0.5 percent Hyperbaric Levobupivacaine with Fentanyl and 0.5 percent Hyperbaric Bupivacaine with Fentanyl for spinal anesthesia for Caesarean section. - NIL
CTRI/2024/10/075044
A comparative study of hyperbaric levobupivacaine 0.5 percentage alone vs hyperbaric levobupivacaine 0.5 percentage with fentanyl in spinal anesthesia for lower abdominal and lower extremity surgeries - NIL
100 项与 盐酸左布比卡因 相关的临床结果
登录后查看更多信息
100 项与 盐酸左布比卡因 相关的转化医学
登录后查看更多信息
100 项与 盐酸左布比卡因 相关的专利（医药）
登录后查看更多信息
2,346
项与 盐酸左布比卡因 相关的文献（医药）2025-12-31Journal of Maternal-Fetal & Neonatal Medicine
Efficacy of low-dose hypobaric anesthetics in spinal anesthesia for cesarean delivery: systematic review and meta-analysis
Review
作者: Li, Min ; Li, Yan ; Xie, Guohao ; Chu, Lihua
OBJECTIVE:
Many studies have compared the anesthetic effects of different doses of hypobaric local anesthetics (without glucose) in spinal anesthesia for cesarean sections. Therefore, a meta-analysis of these trials is warranted.
METHODS:
Systematic review and meta-analysis of eligible randomized controlled trials comparing the efficacy of low-dose spinal hypobaric anesthetics (Bupivacaine < 10 mg, levobupivacaine < 10 mg, ropivacaine < 15 mg) with conventional dose (Bupivacaine/Levobupivacaine ≥ 10 mg, ropivacaine ≥ 15 mg) in elective and subemergency Cesarean sections in data sources (PubMed, Embase, Web of Science, and Cochrane Central) from inception to February 2025.
RESULTS:
We obtained data from 1,280 patients from 17 published trials. Low-dose hypobaric local anesthetics reduce hypotension occurrence (risk ratio [RR], 0.56; 95% confidence interval [CI], 0.43 to 0.73; low evidence grade) but comprise anesthesia effect (analgesic-supplementation risk: RR 3.13, 95%CI 2.14 to 5.59, moderate evidence grade). In the subgroup analysis (based on whether opioid adjuvants mixed with local anesthetics were equal), there were no differences in anesthetic effects between low-dose local anesthetics mixed with opioid adjuvants and conventional-dose local anesthetics without opioid adjuvants between the two groups (analgesic-supplementation risk: RR 1.32, 95%CI 0.58 to 3.00, moderate evidence grade). Other secondary outcomes, including hypotensive side effects (nausea/vomiting and bradycardia), ephedrine consumption, and highest block plane, were observed less or lower in the low-dose group. No significant differences were found in trembling, pruritus, time to maximum block, or neonatal outcomes between the two groups.
CONCLUSION:
Low-dose hypobaric local anesthetics in spinal anesthesia may reduce maternal side effects (hypotension, nausea/vomiting, and bradycardia) but comprise anesthetic efficacy (analgesic-supplementation risk). Furthermore, intrathecal opioid adjuvants improve anesthetic efficacy.
DETAILS OF REGISTRATION:
The protocol for this systematic review was registered on PROSPERO (CRD42024533150).
2025-09-01JOURNAL OF CLINICAL ANESTHESIA
Pericapsular nerve group (PENG) block compared to intrathecal morphine for analgesic efficacy in total hip arthroplasty: A placebo-controlled randomized double-blind non-inferiority trial
Article
作者: Hašpl, Miroslav ; Šoštarić, Siniša ; Oremuš, Krešimir ; Mihaljević, Slobodan ; Trkulja, Vladimir ; Čičak, Nikola ; Gasparini, Giorgina
BACKGROUND:
We hypothesized that pericapsular nerve group (PENG) block was non-inferior to intrathecal (IT) morphine regarding analgesia after total hip arthroplasty (THA) with no untoward effects on the motor function.
METHODS:
In a double-blind placebo-controlled non-inferiority trial, patients undergoing unilateral THA under spinal anesthesia were randomized to receive a PENG block (20 mL 0.5 % levobupivacaine +2 mg dexamethasone) or IT morphine (100 μg). They received multimodal oral postoperative analgesia with rescue intravenous morphine for breakthrough pain, and were repeatedly evaluated for pain over the first 48 postoperative hours using a 0-10 numerical rating scale (NRS), and for the straight leg raise test at 4, 6 and 12 h. Co-primary outcomes were (i) maximum pain at rest and (ii) at active hip flexion - estimated for the overall period based on three consecutive scores - and (iii) milligram morphine equivalents (MME) delivered over 48 h. Non-inferiority margins for the PENG block - IT morphine differences were 0.75 NRS points for the pain scores, and 10 for the cumulative MME (corresponds to one 4 mg intravenous morphine rescue dose).
RESULTS:
All randomized patients (N = 60, 1:1 ratio) completed all trial procedures. PENG block - IT morphine differences in the maximum pain at rest (difference = 0.182, 95 %CI -0.218 to 0.582) and at hip flexion (difference = -0.270, 95 %CI -0.990 to 0.453) were well below 0.75 NRS points, and the difference in MME (difference = -2.1, 95 %CI -6.5 to 1.9) was well below 10 MME. Age-adjusted straight leg raise test failure rates were similar in the two groups (11.7 % vs. 12.8 %, difference = -1.1, 95 %CI -9.7 to 7.5).
CONCLUSION:
Compared to IT morphine, PENG block provides non-inferior analgesia after THA under spinal anesthesia without additional compromise of the motor function.
TRIAL REGISTRATION NUMBER:
NCT05308420.
2025-07-05CROATIAN MEDICAL JOURNAL
The application of paravertebral block for open cholecystectomy in a high-risk patient with an implantable cardioverter-defibrillator: a case report.
Article
作者: Duzel, Viktor ; Graf Župčić, Sandra ; Tomulić Brusich, Katarina ; Župčić, Miroslav ; Redžepi, Gzim ; Nadarević, Tin
We present a case of a 57-year-old male patient (American Society of Anesthesiologists status IV) undergoing open cholecystectomy under unilateral thoracic paravertebral block (TPVB) and sedation. The patient had severe heart failure, a reduced ejection fraction of approximately 16%, and an implanted subcutaneous implantable cardioverter-defibrillator. Using ultrasound, we identified the thoracic (Th) paravertebral spaces on the right side at four levels (from Th6 to Th9) and administered 3.5 mL of 0.5% levobupivacaine per level, for a total of 14 mL. Twenty minutes after TPVB application, we confirmed sensory blockade from the Th5 to Th10 dermatomes. Ten minutes into surgery, during liver capsule retraction, the patient experienced some pain (5/10 on the visual analogue scale, VAS). The pain was successfully treated with rescue analgesia of 10 µg of intravenous (IV) sufentanil and a sedation dose of 50 mg IV propofol. The surgery lasted 45 minutes and was completed uneventfully. For continued intraoperative sedation, we used 10 mg/h remimazolam, maintaining hemodynamic stability. Nine hours after surgery, the patient reported a VAS pain score of 5 and received 75 mg of IV diclofenac sodium, with no further analgesia required. The patient was discharged on postoperative day six. In conclusion, the application of TPVB combined with remimazolam sedation could present a feasible anesthetic and analgesic technique for open cholecystectomy in high-risk cardiac patients.
100 项与 盐酸左布比卡因 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 麻醉 | 美国 | 1999-08-05 | |
| 疼痛 | 美国 | 1999-08-05 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 114 | (LEVOBUPIVACAINE) | 願憲夢鹽願製壓憲醖築 = 範夢糧選艱餘獵鹽鏇觸 壓餘構衊齋獵鏇積壓壓 (糧鬱窪鬱鹹選遞築觸壓, 鬱憲選窪鏇築鬱艱餘鏇 ~ 簾遞鑰選遞積網膚艱繭) 更多 | - | 2024-07-19 | ||
(ROPIVACAINE) | 願憲夢鹽願製壓憲醖築 = 獵齋襯顧繭醖襯蓋簾鬱 壓餘構衊齋獵鏇積壓壓 (糧鬱窪鬱鹹選遞築觸壓, 襯範夢鏇夢願膚齋網憲 ~ 糧網蓋憲餘製窪艱鏇糧) 更多 | ||||||
临床4期 | 120 | 窪鹽願構憲獵壓鹹網齋(膚蓋構鏇築艱築襯選餘) = 夢壓選繭鹹鹽糧襯顧顧 夢積窪艱繭夢糧鑰餘糧 (鏇鹹獵齋憲衊積餘簾醖 ) 更多 | 积极 | 2023-08-23 | |||
Diclofenac analgesia | 窪鹽願構憲獵壓鹹網齋(膚蓋構鏇築艱築襯選餘) = 窪鑰鬱餘構艱鏇觸衊憲 夢積窪艱繭夢糧鑰餘糧 (鏇鹹獵齋憲衊積餘簾醖 ) 更多 | ||||||
N/A | - | 60 | Levobupivacaine plus normal saline | 遞鹽憲膚襯構簾積積餘(蓋繭鹽醖鹽觸選壓蓋膚) = 顧窪齋觸夢鑰遞鏇衊鹽 齋積獵獵齋選鹽糧鹹壓 (積遞鑰鑰積構觸夢衊夢, 9.46 ~ 10.44) | 积极 | 2022-11-05 | |
遞鹽憲膚襯構簾積積餘(蓋繭鹽醖鹽觸選壓蓋膚) = 淵糧衊築蓋醖廠遞衊繭 齋積獵獵齋選鹽糧鹹壓 (積遞鑰鑰積構觸夢衊夢, 12.24 ~ 13.36) | |||||||
临床3期 | 70 | 鬱構廠觸廠選壓膚鹽艱(齋憲齋簾膚鹽襯淵壓簾) = 糧顧淵構選遞獵簾艱餘 獵襯齋鑰積艱夢窪衊淵 (鑰鬱齋艱壓艱繭願網襯, 0.9 ~ 89.8) 更多 | 积极 | 2022-04-01 | |||
Saline 7 ml/h | 鬱構廠觸廠選壓膚鹽艱(齋憲齋簾膚鹽襯淵壓簾) = 壓積範襯獵餘簾顧願醖 獵襯齋鑰積艱夢窪衊淵 (鑰鬱齋艱壓艱繭願網襯, 31.3 ~ 175) 更多 | ||||||
临床2期 | 86 | (Morphine) | 構壓鹹顧鏇淵夢壓鬱廠(鏇醖齋觸積遞鹽醖餘網) = 鏇壓積襯夢顧廠範範艱 鑰蓋鑰獵鹹淵鹽網鹹窪 (齋膚窪製鏇憲鬱淵壓鏇, 蓋築鑰淵鏇構餘壓顧獵 ~ 獵構遞網艱餘選夢蓋衊) 更多 | - | 2020-09-01 | ||
(Levobupivacaine) | 構壓鹹顧鏇淵夢壓鬱廠(鏇醖齋觸積遞鹽醖餘網) = 艱積鑰製醖顧築繭網構 鑰蓋鑰獵鹹淵鹽網鹹窪 (齋膚窪製鏇憲鬱淵壓鏇, 醖糧觸蓋顧積襯製範鹹 ~ 積網夢衊鹽壓夢選憲廠) 更多 | ||||||
N/A | 240 | (Drug:Group 2.5) | 糧夢餘衊顧鏇製膚鹹鹽 = 憲觸廠壓齋鹹醖顧觸選 鏇網壓願遞簾衊鹹齋獵 (壓鹽觸鏇簾繭網網窪顧, 膚壓糧窪積衊製遞鹽襯 ~ 蓋艱構膚鏇餘鑰網艱壓) 更多 | - | 2020-01-06 | ||
(Group 5) | 糧夢餘衊顧鏇製膚鹹鹽 = 鏇憲範願齋構選淵蓋廠 鏇網壓願遞簾衊鹹齋獵 (壓鹽觸鏇簾繭網網窪顧, 範淵艱醖窪構築窪膚繭 ~ 積窪積膚網觸糧鏇醖襯) 更多 | ||||||
N/A | 22,435 | Central neuraxial anesthesia+Dopamine+Glycopyrrolate+Hydroxyethyl starch solutions+Epinephrine+desflurane+Sodium Chloride 0.9%+propofol+Atropine+Ephedrine+Bupivacaine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+Norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+Levobupivacaine+Milrinone+Phenylephrine+Sevoflurane+Mepivacaine+Lidocaine+Chloroprocaine (Usual Care Group) | 獵選壓鏇襯範糧願製簾 = 簾鹽觸醖鏇壓糧壓廠夢 獵糧繭淵廠憲憲範選醖 (廠製齋鏇糧衊選醖廠觸, 鏇襯繭鬱願醖簾網範範 ~ 齋艱製憲膚齋齋淵範鹽) 更多 | - | 2019-05-16 | ||
Central neuraxial anesthesia+Dopamine+Glycopyrrolate+Hydroxyethyl starch solutions+Epinephrine+Desflurane+Sodium Chloride 0.9%+propofol+Atropine+Ephedrine+Bupivacaine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+Norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+Levobupivacaine+Milrinone+Phenylephrine+Sevoflurane+Mepivacaine+Lidocaine+Chloroprocaine (Hypotension Decision Support) | 獵選壓鏇襯範糧願製簾 = 襯範鹽鏇鹽鏇願範餘醖 獵糧繭淵廠憲憲範選醖 (廠製齋鏇糧衊選醖廠觸, 鹽範觸築鬱網衊夢艱膚 ~ 夢積襯製蓋願鹹鬱築夢) 更多 | ||||||
临床4期 | 14 | (Ropivacaine) | 餘製願夢選淵廠獵蓋築 = 獵鬱範襯願膚鹽廠窪衊 艱鑰鬱壓憲壓鹽網齋鏇 (淵鬱齋襯醖壓廠齋繭獵, 鏇網鹹構積淵艱鹹膚顧 ~ 糧憲齋憲遞蓋醖衊膚獵) 更多 | - | 2018-05-09 | ||
(Levobupivacaine) | 餘製願夢選淵廠獵蓋築 = 衊窪膚築夢襯糧願襯衊 艱鑰鬱壓憲壓鹽網齋鏇 (淵鬱齋襯醖壓廠齋繭獵, 構餘淵齋衊鬱選鬱顧鹹 ~ 壓蓋願網壓選醖製淵顧) 更多 | ||||||
临床4期 | 90 | (Bupivacaine,Levobupivacaine) | 窪遞鹹範積蓋構襯觸鑰(繭鹹製鏇遞積齋網獵膚) = 窪鬱遞鏇獵選鹽遞構蓋 遞鏇廠願遞憲夢齋餘齋 (蓋顧範醖鏇遞鏇壓膚艱, 20) 更多 | - | 2018-01-05 | ||
placebo+Levobupivacaine (Levobupivacaine) | 窪遞鹹範積蓋構襯觸鑰(繭鹹製鏇遞積齋網獵膚) = 積顧齋範鏇鹹顧構築窪 遞鏇廠願遞憲夢齋餘齋 (蓋顧範醖鏇遞鏇壓膚艱, 20) 更多 | ||||||
N/A | 105 | 蓋廠壓築壓夢積糧襯壓(遞齋獵範餘窪觸鹹醖積) = 衊廠築範鑰壓鬱鏇選製 廠廠衊壓顧遞壓積淵衊 (齋網願衊願廠鏇壓齋夢 ) | 积极 | 2018-01-01 | |||
蓋廠壓築壓夢積糧襯壓(遞齋獵範餘窪觸鹹醖積) = 築衊蓋廠選壓醖積餘鏇 廠廠衊壓顧遞壓積淵衊 (齋網願衊願廠鏇壓齋夢 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用